Madam Speaker, again, I thank the member for his thoughtful and considerate way of approaching this really important issue.
As I mentioned in my response earlier, there is a priority review that is going on, which requires an expeditious review of the process and the timelines that are associated with it. It requires, of course, the sponsor or the manufacturer of the medication to provide all the necessary data for Health Canada to review.
The information that I have available to me is that there is no indication that the process is not taking place. I understand that it is taking place. I am hopeful that, for the sake of Canadians who are suffering from PAH, the review will be completed and approval granted in the requisite time. However, that is not my decision. No politician should be making those types of decisions. That is the decision of officials at Health Canada, ensuring that the health and safety of Canadians remain paramount.